StockMarketWire.com - Drug discovery group C4X Discovery Holdings said it had entered into an exclusive partnership with gene editing company Horizon Discovery Group.
The partnership would aim to validate synthetic lethal oncology targets that had been identified by Horizon's technology.
The work would lead to the generation of potential new drugs for patients with limited effective treatments, such as for colorectal and lung cancer.
C4XD would apply its chemistry technology to discover the drug candidates.
'This partnership with Horizon gives C4XD access to a comprehensive proprietary CRISPR screening dataset that has selected the most promising novel drug targets in colon and lung cancer,' chief scientific officer Craig Fox said.
'We look forward to working with the highly experienced team at Horizon to complete the target validation package for these novel genes and initiate drug discovery programmes to generate high value pre-clinical licensable assets for partnering.'
At 3:01pm: (LON:C4XD) C4x Discovery Holdings Plc share price was +1p at 76p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.